DAJY(SZ:002030)2023-12-19 17:30Group 1: Company Overview - The main business of the company is molecular products, with subsidiaries involved in immunology and biochemistry, covering the entire field of in vitro diagnostics [1] - The company has been actively obtaining various medical device certifications [1] Group 2: Financial Status - The company currently has sufficient cash flow to support daily operations and R&D investments, with no immediate plans for refinancing [2] Group 3: Market Opportunities - The pandemic has provided both opportunities and challenges, necessitating a focus on product innovation that offers cost-effective solutions for the public [2] - The company aims to diversify its product line through technological innovation to meet varying consumer needs and expand market share [2] Group 4: International Expansion - The company has exported PCR products to over 140 countries and has a complete product chain consisting of core raw materials, reagents, instruments, and supporting consumables [2] - Future plans include continued active exploration and expansion into overseas markets [2]